|11.50||-0.02 / -0.17%|
As of 4:14pm ET
|11.50||0.00 / 0.00%|
The 7 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 16.00, with a high estimate of 19.00 and a low estimate of 9.00. The median estimate represents a +39.13% increase from the last price of 11.50.
The current consensus among 8 polled investment analysts is to Buy stock in Nektar Therapeutics. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.